安旭生物收盘下跌1.13%，滚动市盈率30.51倍，总市值47.63亿元

Company Overview - Anxu Bio focuses on the research, production, and sales of POCT reagents and instruments, and has been recognized as a "Zhejiang Province Intellectual Property Demonstration Enterprise" and a "National Intellectual Property Advantage Enterprise" [1] - As of March 31, 2025, Anxu Bio had 5,935 shareholders, a decrease of 278 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Financial Performance - For Q1 2025, Anxu Bio reported revenue of 115 million yuan, a year-on-year decrease of 10.90%, and a net profit of 34.03 million yuan, down 51.52% year-on-year, with a gross profit margin of 42.32% [1] Market Position - Anxu Bio's current rolling price-to-earnings (PE) ratio is 30.51, while the average PE ratio for the medical device industry is 49.10, and the industry median is 36.43, placing Anxu Bio at the 69th position in the industry ranking [1][2] - The company's total market capitalization is 4.763 billion yuan [1][2] Intellectual Property and Certifications - In 2024, Anxu Bio added 44 new authorized patents, including 13 invention patents, bringing the total to 305 authorized patents, of which 43 are invention patents [1] - The company has obtained multiple authoritative certifications, including EU CE certification, Canadian certification, and Australian certification, with a total of 1,580 certifications, including 606 new certifications in the latest period [1]